

CONTENTS

Vol.44 No.4 July 2013

Japanese Journal of Clinical Pharmacology
and Therapeutics

Original Article

- | | | |
|--|------------------------|-----|
| Lack of Pharmacokinetic Interaction between Pilsicainide and Rifampicin in Healthy Volunteers | Tsuyoshi SHIGA, et al. | 301 |
| Bioequivalence in Safety and Pharmacokinetics of Fentanyl Tape for 3 Days after a Single Application in Japanese Healthy Male Subjects | Ken SHIMADA, et al. | 307 |
| Co-Administrated Naltrexone Hydrochloride | Ai KANDA, et al. | 313 |
| Survey on "Renal Function" Information in the Package Inserts of Prescription Drugs | | |

Case Report

- | | | |
|---|-------------------------|-----|
| A Narrative Approach in Psychological Aspects of Four Participants in a Placebo-Controlled Double-Blind Trial of Cancer Chemotherapy: A Case Report | Takako FUJITANI, et al. | 319 |
|---|-------------------------|-----|

Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

- | | | |
|---|--|-----|
| Contents | | 323 |
| "How Can We Assess Efficacy and Safety of Approved Drugs?" | | 325 |
| Symposium 5 "Efficient Supply of Post-Marketing Information of Drugs" | | 339 |
| Symposium 11 "Pharmacokinetics Study on Patients" | | 349 |
| Symposium 19 "Personalized Medicine Based on Pharmaceutical Care" | | 359 |
| Symposium 20 "What is Needed for Early Phase Clinical Studies in Japan to be Internationally Recognized?" | | 367 |

Report

- | | | |
|---|-----------------------|-----|
| Report of Trainee of the Foreign Clinical Pharmacology Training Program: No.4 | Atsushi SAKURABA | 379 |
| Report of Trainee of the Foreign Clinical Pharmacology Training Program: No.1 | Mihoko YAMADE | 383 |
| Report of CRC Trainee of the Foreign Clinical Pharmacology | Mitsuo KIMATA, et al. | 385 |

Drug Information

121E

Information for Authors

125E

Announcements

127E

Contents of Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

“How Can We Assess Efficacy and Safety of Approved Drugs?”

1. Clinical Epidemiology of Adverse Drug Events	Takeshi MORIMOTO	325
2. Evaluation of Safety and Efficacy of Medicine in the Registry after Coronary Revascularization	Masahiro NATSUAKI, et al.	329
3. Safety and Efficacy Evaluation of Cardiovascular Drugs after Approval	Reiko SATO	334
4. Registry Based Comparative Effectiveness Research	Shinichiro UEDA	335

Symposium 5 “Efficient Supply of Post-Marketing Information of Drugs”

Summary	Masahiro NOMOTO, et al.	339
1. Outline of Risk Management Plan	Shinichi WATANABE	341
2. Supply and Utilization of Useful Post Marketing Information in Medical Field --From a Physician’s Viewpoint--	Hideki MOCHIZUKI	343
3. Problem in Post-Marketing Supply of Information --Mainly in Package Leaflet--	Hiroaki ARAKI	345
4. Providing Proactive and Timely Information Resulting from Ongoing Post-Marketing Studies to Medical Institutes	Yasuhiko KAI, et al.	347

Symposium 11 “Pharmacokinetics Study on Patients”

Summary	Yukiko MARUYAMA, et al.	349
1. The Implementation System in Ehime University Hospital for Pharmacokinetic Studies of Patients	Risako YAMASHITA, et al.	351
2. Problems in Performing Pharmacokinetic Examinations in Men with Pathological Conditions	Kazuhiro HARADA	353
3. PK/PD Study in Patients in Phase 1 Unit	Hinako UCHIMARU, et al.	355
4. Request to Japanese Medical Institution to Promote Clinical PK/PD Trial in Patients	Shingo MATSUI	357

Symposium 19 “Personalized Medicine Based on Pharmaceutical Care”

1. An Approach to Personalized Medicine	Hiroki ITO	359
2. Application of Gene Analysis and TDM in Personalized Drug Therapy	Tomonori NAKAMURA, et al.	361
3. Adverse Event Monitoring	Toshiaki NAKAMURA, et al.	363
4. Expectation for Clinical Pharmacology from Bed Side	Tohru HASHIDA	365

Symposium 20 “What is Needed for Early Phase Clinical Studies in Japan to be Internationally Recognized?”

Summary	Masako NAKANO, et al.	367
1. FIH Study: In Order to Conduct Successful Global Exploratory Studies	Kazuo UMEMURA	369
2. Proof of Concept Trials	Masahiro NOMOTO	371
3. Conducting Phase 1 Study in Patient Subjects: Points to Consider	Masanari SHIRAMOTO, et al.	373
4. FIH (First-in-Human) Trial of Oncology Drug Products: How to Enhance International Competitiveness of Japanese Academic Hospitals	Yasuhiro FUJIWARA	375
5. Promotion of Early Stage Clinical Trials: From the Viewpoint of MHLW	Masanobu YAMADA	377